• <tr id="yyy80"></tr>
  • <sup id="yyy80"></sup>
  • <tfoot id="yyy80"><noscript id="yyy80"></noscript></tfoot>
  • 99热精品在线国产_美女午夜性视频免费_国产精品国产高清国产av_av欧美777_自拍偷自拍亚洲精品老妇_亚洲熟女精品中文字幕_www日本黄色视频网_国产精品野战在线观看 ?

    Programmed polymersomes with spatio-temporal delivery of antigen and dual-adjuvants for efficient dendritic cells-based cancer immunotherapy

    2022-09-15 03:10:50HanyongWangXinyuYangChunyanHuChenluHuangHaiWangDunwanZhuLinhuaZhang
    Chinese Chemical Letters 2022年9期

    Hanyong Wang, Xinyu Yang, Chunyan Hu, Chenlu Huang, Hai Wang, Dunwan Zhu,Linhua Zhang

    Tianjin Key Laboratory of Biomedical Materials, Key Laboratory of Biomaterials and Nanotechnology for Cancer Immunotherapy, Institute of Biomedical Engineering, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin 300192, China

    ABSTRACT Since antigen and adjuvant are rapid clearance in vivo, insufficient delivery to induce dendritic cells (DCs)maturation and cross-presentation, as well as limited migration efficiency of DCs to secondary lymph organs, greatly hinders the development of DCs-based immunotherapy.Herein, PCL-PEG-PCL polymersomes(PCEP-PS) as antigen and adjuvants delivery nanoplatforms (IMO-PS) were well-designed, which can electrostatically adsorb OVA antigen on the surface via DOTAP lipid and effectively encapsulate OVA antigen into the inner hydrophilic cavity to achieve both initial antigen exposure as well as slow and sustained antigen release, incorporate MPLA within the lipid layer to ligate with extracellular TLR4 of DCs as well as encapsulate IMQ in the hydrophobic membrane to ligate with intracellular TLR7/8 of DCs for activating synergistic immune responses via different signaling pathways.The IMO-PS significantly improved antigen uptake, promoted DCs maturation and cytokines production.DCs treated with IMO-PS could enhance migration into draining lymphoid nodes, and eventually induced antigen-specific CD8+ and CD4+T cell responses and OVA-specific cytotoxic T lymphocyte (CTL) responses.Prophylactic vaccination of EG7-OVA tumor-bearing mice by IMO-PS+DCs significantly extended tumor-free time, effectively suppressed tumor growth, and greatly extended median survival time.The strategy may provide an effective nanoplatform for co-delivery antigen and dual-adjuvants in a spatio-temporally programmed manner for DC-based cancer immunotherapy.

    Keywords:DCs vaccine Immunotherapy Imiquimod MPLA DOTAP OVA

    As professional antigen-presenting cells, dendritic cells (DCs)play pivotal roles in both innate and adaptive immune responses[1].By processing captured antigen into peptides, DCs present them to lymphoid organs to initiate T cell or B cell immunity [2–4].Recently, DCs have been extensively used in developing DCsbased immunotherapy to treat cancer [5].DCs-based therapy includesin vitroloading of DCs with tumor or pathogen-associated antigens, activating and maturing the cells, and then reinjecting the DCs back to activate T cellsin vivo[6–8].Although DCs-based immunotherapy exhibits safety and immunogenicity, clinical responses have been largely unsatisfactory [9].There are several pitfalls restricting the effects of DCs vaccines.Among them, the main pitfall is few (~0.5%–2%) injected DCs can migrate to the lymph nodes (LNs), which hinders effective induction of T cell responses.Another drawback is inefficient stimulation of DCs to induce their maturation for the subsequent antigen-presentation to T cells, which is essential for effective DCs-based immunotherapy[1].

    Nanotechnology offers unique opportunities to tackle the clinical challenges faced by current DCs-based immunotherapy.Nanoparticles can be designed to act on DCs and regulate their functions in several distinct ways: by delivering or acting as adjuvants to optimize DCs activation, enhancing antigen internalization by targeting to DCs, facilitating exogenous antigen crosspresentationvialysosome escape, incorporating different vaccine components to help DCs to govern the activation of CD4+and CD8+T cells, or exerting intrinsic immunomodulation effect on DCs [8,10–12].Rincon-Restrepoet al.demonstrated that antigen encapsulated within the nanoparticles preferred CD4+T cell activation while antigen decorated onto the surface of NPs primarily led to CD8+T cell responses [13].Hence, nanoparticles with both surface-attached and core-encapsulated antigen might result in both CD4+and CD8+immune responses.Among various nanoparticles, polymersomes have a unique structure in which an aqueous core is enveloped by a bilayer membrane formulated by amphiphilic copolymers, entitling the vesicles with the capability of encapsulating both hydrophobic and hydrophilic molecules[14].The potential to encapsulate bioactive molecules with various physicochemical properties makes polymersomes a flexible vehicle to incorporate both antigen and adjuvants.In addition,the surface of the polymersomes can be easily further decorated with cationic lipid, which can complex with anionic peptides or proteins to generate immune responsesin vivo.1,2-dioleoyl-3-trimethylammonium-propane (DOTAP) has been widely investigated in forming cationic liposome.DOTAP not only can adsorb anionic antigen to form vaccine carrier but also can facilitate antigen escape from the lysosome into the cytosolviaits ‘proton sponge’effect in acidic condition [15,16].Only after lysosome escape can the antigen be presentedviaMHC Ⅰpathway to activate CD8+T cells and elicit cytotoxic T-lymphocytes (CTL) response.

    Many studies demonstrated that immature DCs can be effectively activated by toll like receptor (TLR) agonists, leading to their maturation and migration to the draining LNs, where they can stimulate effector T cells [17,18].In addition, activation of TLRs on immune cells can promote the secretion of pro-inflammatory cytokines such as IL-6, IL-12 and TNF-α, leading to enhanced innate and adaptive responses [19,20].TLR family members can be divided into endosome-associated and cell-membrane-associated receptors [21].R837 (imiquimod, IMQ) is an endosome-associated agonist for TLR7 and TLR8, which can activate DCs and induce the secretion of various pro-inflammatory factors [22].Monophosphoryl lipid A (MPLA), a detoxified form of lipopolysaccharide (LPS),can interact with membrane-associated TLR4 on DCs and activate DCs.MPLA has been repeatedly shown to enhance the release of pro-inflammatory cytokines and induce stronger T helper 1 (Th1)-biased immune responses [23,24].TLR7/8 signaling depends on myeloid differentiation primary-response gene 88 (MyD88) pathways, while TLR4 signaling is dependent on both of the My88 and TIR-domain-containing adaptor protein inducing IFN-β(TRIF) pathways [25,26].Activation of multiple signaling pathways from both the cell surface and endosome could spatially and temporally induce immune responses that are synergistic [27].TLR7/8 and TLR4 co-stimulation has been reported to significantly increase IL-12 secretion and skew DCs to improve Th1-biased responses [28,29].

    Based on the hypothesis that the immunological efficacy of lipid-polymeric hybrid NPs can be enhancedviaincorporating appropriate molecules, this study aims to compare whether the combination of both endosome-associated and cell-membraneassociated TLR agonist can achieve the highest efficacy in DCsbased immunotherapy.OVA-loaded polymersomes containing both TLR agonist MPLA and IMQ (IMO-PS), single agonist (MO-PS and IO-PS), or without agonist (O-PS) were fabricated and characterized in terms of size and size distribution, zeta potential, and OVA loading amounts.Then, immature DCs were treated with these OVAloaded polymersomes to obtain DCs-based vaccine.The cell viability, cellular uptake and effect of various OVA-loaded polymersomes on DCs maturation, cytokine secretion, and antigen crosspresentation were evaluated.In addition,in vivotracking study was carried out to evaluate the homing ability of DCs-based vaccine.Furthermore,in vivointracellular IFN-γproduction, OVA-specific CTL responses, and prophylactic vaccination effect of various DCsbased vaccines against EG7-OVA tumor model were assessed.Our study revealed that IMO-PS stimulated DCs were more efficient in cancer immunotherapy than MO-PS or IO-PS stimulated DCs,demonstrating enhanced effect of OVA-loaded polymersomes with dual agonists on DCs-based immunotherapy.

    OVA-loaded polymersomes were synthesized and characterized in our study.PCL-PEG-PCL polymersomes (PCEP-PS) co-delivery of immunostimulant molecules and OVA modal antigen were fabricated by a W/O/W method.Using this method, PCEP polymer formed an aqueous hydrophilic PEG core to encapsulate OVA inside and hydrophobic PCL membrane layer to incorporated lipophilic TLR7 agonist IMQ.TLR4 agonist MPLA was anchored into the lipid layer and outside OVA was absorbed on the outer layer of the PS surface by electronic interaction with DOTAP lipid (Fig.S1 in Supporting information).The physical parameters of the formulated PCEP-PS and the loading amounts of OVA were summarized in Table S1 (Supporting information).The average size of the PCEP-PS was detected by dynamic light scattering (DLS) and TEM.Both techniques exhibited that the hydrodynamic diameter of these PCEP-PS was ranged from 250 nm to 300 nm with a PDI of 0.31–0.41.Nanoparticles with this size are reported to effectively activate DCs and induce systemic immune responses compared to bigger particles [30].As shown in Fig.S2A (Supporting information), the TEM image showed that OVA-loaded PS had a spherical shape with some visible particles on the surface, demonstrating successfully adsorption of OVA.The zeta potential was slightly negative, indicating that the OVA was successfully absorbed on the outer layerviacationic DOTAP lipid.OVA was efficiently encapsulated in PCEP-PS with a loading amount ranged from 45 μg/mg to 57 μg/mg PS, indicating their great capability of loading antigen(Table S1).

    In vitroOVA release study was conducted in mimicking normal physiologic microenvironment (PBS, pH 7.4).Representative cumulative release curve of OVA from polymersomes was shown in Fig.S2B (Supporting information).About 20% of the antigen was released from IMO-PS within 24 h and 70% of the antigen was then continuously released for 28 days.Antigen release is one of the most important factors for particle-based vaccination.Prolonging antigen release can enable antigen persistence to immune cells, which is favorable to induce robust T cell responses [31].Meanwhile, initial antigen exposure is also important due to the quick induction of antigen-specific immune responses.The combined quick and slow antigen release from the well-designed IMOPS provided not only initial antigen exposure but also long-term antigen persistence, which was critical to enhance immune responses.

    To ensure the loading of OVA-Cy7 in PECP-PS, we usedin vivoimaging system to acquire NIR fluorescence images of prepared OVA-loaded PS.Fig.S2C (Supporting information) showed that all OVA-loaded PS groups exhibited equivalent fluorescence, while no fluorescence signals were detected in PBS group.To determine the DC labeling efficiency, DCs were incubated with OVA-Cy7 loaded PS at various concentrations (25, 50, 100 or 200 μg/mL) for 16 h and then NIR fluorescence images were obtained.As shown in Fig.S2D (Supporting information), the fluorescence signal intensity increased with the increase of concentration, and intensive NIR fluorescence from the pelleted DCs were observed at concentration higher than 50 μg/mL.

    For DC-based immune therapy, the injected DCs should be capable of keeping viable long enough to migrate to the secondary lymphoid organs and trigger an immune response.Thus, the viability of DCs after incubating with OVA-loaded PS was critical to achieve effective therapy.DC viability was assessed after being treated with various OVA-loaded PS at different OVA concentrations (25 and 50 μg/mL) for 24 and 48 h.As shown in Figs.1A and B, no cytotoxic effect was observed on BMDCs after incubating with free OVA or OVA-loaded PS, indicating the high cytocompatibility and safety of the formulated antigen carriers.

    Fig.1.Cell viability assay and in vitro PCEP-PS uptake.(A, B) Viability of DCs after treating with various OVA-loaded PCEP-PS at different OVA concentrations (A:25 μg/mL; B: 50 μg/mL) for 24 and 48 h.(C) CLSM images of antigen intracellular localization after incubating DCs with free OVA, O-PS, IO-PS, MO-PS and IMO-PS for 16 h.(D) The percentage of antigen uptake by DCs using flow cytometry analysis.???P < 0.001.

    Antigen uptake, the processing and presentation by DCs is an important step for initializing long-time memory and adaptive immunity.CLSM was used to investigate the cellar uptake and lysosome escape.As shown in Fig.1C, obvious green OVA fluorescence was observed in all the PCEP-PS groups, while very weak signal was detected in the free OVA group.This result demonstrated that PCEP-PS greatly facilitated antigen internalization by DCs.In addition, FITC-OVA was perfectly co-localized with lysosomes in free FITC-OVA group, confirming antigen degradation and processingviathe endosome/lysosome pathway.For PCEP-PS groups, although most of FITC-OVA were co-localized with lysosomes, some of them were found in the cytosol.Antigen release into cytosol is beneficial to cross-presentation for the further activation of CD4+and CD8+T cells [32,33].Antigen delivery systems mediated by NPs have been reported to be more efficient in facilitating APCs to crosspresent antigen [34–36].In our study, the lysosome escape might result from the “proton sponge” effect of cationic DOTAP, which could lead to osmotic swelling and lysosome rupture, thereby causing the cytosolic release of antigens [37].The intracellular localization of OVA confirmed that PCEP-PS enabled the endocytic delivery of exogenous antigen for presenting through both MHC I and MHC II pathways.Since TLR7 is primarily localized in the endosomal region of DCs, efficient IMQ released from the membrane of IO-PS and IMO-PS in the endosome could beneficially promote the interaction of TLR7 and IMQ agonist.The effective internalization of IMO-PS by BMDCs could result in the enhanced synergistic immune activation by both TLR4 and TLR7 signaling pathway.

    The antigen uptake capability of free OVA and various OVAloaded PS was further quantitatively analyzed by FACS.As shown in Fig.1D, free OVA group showed poor antigen uptake efficacy.Compared to O-PS, the OVA-loaded PS with TLR4 and/or TLR7 agonist (IO-PS, MO-PS and IMO-PS) showed significantly higher OVA delivery efficiency into DCs (Fig.1D).OVA-loaded PCEP-PS remarkably enhanced antigen uptake by DCs than free OVA did, contributing to that the cationic DOTAP on the outer layer of the PCEPPS could significantly facilitate antigen internalization by DCs [38].Compared with O-PS, MO-PS increased antigen uptake by DCs,which is in accordance with the previous study that MPLA incorporated in NPs enhanced uptake efficiency of antigens by APCsviathe interaction of MPLA and extracellular TLR4 agonist.Furthermore, IMO-PS group exhibited a higher cell uptake capability than IO-PS and MO-PS, implying that PS encapsulating dual TLRs could provide more efficient ligand internalization.The results above demonstrated that our polymersomes could act as an effective antigen-delivery system for preparing DCs-based vaccine.

    As one of the most important APCs, DCs not only can stimulate innate immune responses but also capture, process and present antigens to na?ve T cells to initiate adaptive immune responses.Immature DCs served as antigen-capturing cells, while mature DCs mainly acted as antigen-presenting cells [39].Thus, we analyzed DCs surface markers and secreted cytokines to assess the possible effects of O-PS, IO-PS, MO-PS and IMO-PS on DCs maturation.It was reported that antigen-loaded DCs kept in a resting state in the absence of activation and maturation stimulation, while they could efficiently facilitate adaptive immune responses when being stimulated by danger signals [40].TLR-based immune adjuvants were reported to induce enhanced expression of maturation markers such as costimulatory (CD80, CD86) molecules on DCs [41].The level of CD80 and CD86 was an important index to assess the immune response in DC-based immunotherapy [42].DOTAP liposomes were reported to improve vaccine-induced immune responses by inducing DC maturation [43].In our studies, different OVA-loaded vaccine formulations were cultured with immature DCs for 24 h, and then CD80 and CD86 expression on CD11c+cells were assessed by FACS.As shown in Fig.S3A (Supporting information), IMO-PS significantly induced higher expression of CD80 than free OVA and O-PS group.IO-PS, MO-PS and IMO-PS had higher expression of CD86 than O-PS.More importantly, the MO-PS and IMO-PS with MPLA agonist on the outer layer significantly elevated the expression of CD86 in comparison to other groups.This was probably due to that MO-PS and IMO-PS can mimic bacterial cell walls and enhance phago- and endo-cytosis by DCs as well as increase expression of costimulatory molecules and production of cytokines when MPLA ligating with TLR4 on DCs surface.Our results demonstrated that directly activating TLRs with IMQ and MPLA could synergistically promote DCs maturation.

    To assess whether immunostimulatory molecules (IMQ and/or MPLA) in PCEP-PS could affect cytokines secretion, DCs were cultured with O-PS, IO-PS, MO-PS and IMO-PS for 24 h.Cell culture supernatants were harvested and diluted to evaluate cytokines (TNF-α, IFN-γ) secretion using ELISA.As elucidated in Fig.S3C (Supporting information), the secretion of IFN-γfrom BMDCs treated with IO-PS, MO-PS, and IMO-PS was 2.0-, 2.4-, and 10.0-fold higher than that treated by O-PS group.Meanwhile, the generation of TNF-αwas also greatly augmented in PCEP-PS group with IMQ and/or MPLA agonist.As shown in Fig.S3D (Supporting information), IO-PS, MO-PS, and IMO-PS group yielded 5.5-,8.0-, and 9.0-fold higher TNF-αgeneration than O-PS group.More importantly, IMO-PS with dual agonists significantly elevated both IFN-γand TNF-αproduction compared to IO-PS and MO-PS with only single agonist.The activation of TLR7 signaling had the potential to induce DCs maturation and stimulate the secretion of proinflammatory cytokines [44,45].MPLA treated DCs were reported to be more efficient at producing Th1 cell-derived cytokine, IFN-γ[46].Our results demonstrated that the co-delivery of both TLR7 and TLR4 agonist within the polymersomes had synergistic effect on promoting the production of pro-inflammatory cytokines, which were important in DCs-based immunotherapy.

    Fig.2. In vivo tracking of various OVA-loaded PS treated DCs (A) NIR images obtained at 3, 6, 9, 24 h after injecting free OVA, O-PS and IMO-PS treated DCs(2×106) into the right footpad of C57BL/6 mice.(B) Inguinal lymph node homing of free OVA, O-PS and IMO-PS treated DCs (PBS treated group was set as control).

    Cross-presentation of endocytosed antigens could activate cytotoxic CD8+T cell and then generate antitumor immunity.To evaluate whether the formulated PCEP-PS could enhance antigen MHC I presentation, DCs were first incubated with OVA-loaded PS and then cocultured with OVA-specific LacZ B3Z CD8+T cells hybridoma.B3Z T cells could produceβ-galactosidase during the process of recognizing OVA SIINFEKL, which is presented by MHC I H-2Kb on DCs.And the producedβ-galactosidase was then quantified by CPRG, aβ-galactosidase substrate, to measure antigen crosspresentation.Fig.S3E (Supporting information) showed that compared to free OVA, OVA-loaded PS increased class I antigen presentation which may due to the increased antigen uptake in OVAloaded PS treated DCs.Furthermore, IMO-PS significantly improved the capability of cross-presentation, which may attribute to the combined effect of immune activator IMQ and MPLA.This data indicated that OVA-loaded PCEP-PS with TLR agonist, especially IMOPS with dual agonists, was superior to antigen alone in activating MHC I cross-presentation.

    In DC-based immunotherapy, migration of antigen-loaded DCs from administrated sites to draining LNsvialymphatic vessels is essential for the induction of adaptive immune responses [47].After migrating to LNs, DCs present the processed antigens in peptide form to CD4+and CD8+T cells and then initiate proper immunity against the antigens [48,49].Nevertheless, subcutaneously injected DCs were reported to migrate to the draining lymphoid tissue in a minority, while the majority were remained at the injected site [50].Thus, enhancing DCs migration into LNs is a key process to improve DC-based immunotherapeutic effect.To explore whether IMO-PS treated DCs could achieve a higherin vivomigration to the LNs, DCs (2×106cells) incubated with free OVA, OPS, and IMO-PS were injected into a left hind-leg footpad of the C57BL/6 mouse.Then, fluorescence signals were observed by thein vivoimaging system.As shown in Fig.2A, Cy7-OVA fluorescence appeared in the inguinal LNs 3 h post injection of IMO-PS treated DCs and keep strong at 24 h, whereas free OVA and OPS treated DCs showed a relatively weak fluorescence at 3 h post injection and almost no fluorescence at 24 h, implying gradual migration of IMO-PS treated DCs from the administration site to the draining lymph node through lymphatic vessels.Furthermore, DCs migration was confirmed byex vivoNIR images of dissected inguinal LNs.Fig.2B showed that IMO-PS treated DCs generated the strongest NIR signals, thus demonstrating their effective migration to the draining LNs.However, immature DCs treated with free OVA and O-PS showed a weak signal.The capability of DCs to migrate into draining LNs is essential for DCs to exert functions.Our results demonstrated that IMO-PS treated DCs remained active and achieved migration to LNs after being injected back into mice.

    To confirm antigen-specific T cell responses in immunized mice,intracellular IFN-γwas evaluated by FACS after 96 hex vivostimulation with SIINFEKL peptide.Co-delivery of antigen and adjuvant to DCs was reported to be important to induce strong CD8+T cell immune response [51].TLR activation of DCs is capable of priming antigen-specific CD4+T-helper cells, which are essential to induce antibody responses [52,53].Representative FACS plots and mean frequencies of IFN-γproducing CD4+and CD8+T cells were shown in Fig.3.As for IFN-γ+CD4+T cell in spleen, the percentage in mice immunized with IMO-PS, IO-PS and MO-PS treated DCs was 1.68% ± 0.12%, 1.22% ± 0.14%, and 1.33% ± 0.10%, respectively.On the contrary, PBS, free OVA and O-PS treated DCs immunized mice were significantly lower, with a percentage of 0.52% ± 0.12%,0.53% ± 0.14%, and 0.55% ± 0.11%, respectively.The percentage of IFN-γ+CD8+T cells detected in spleen of mice immunized with IMO-PS treated DCs was 2.44% ± 0.11%, which was significantly higher than IO-PS treated DCs (1.25% ± 0.13%) and MO-PS treated DCs (1.29% ± 0.11%).Additionally, the amount of IFN-γ+CD8+T cells was remarkably lower in mice immunized with PBS, free OVA and O-PS treated DCs, with a percentage of 0.68% ± 0.12%,0.69% ± 0.14% and 0.74% ± 0.11%, respectively.The data suggested that IMO-PS greatly improved the ability of DCs to induce antigenspecific CD8+and CD4+T cell responses.

    The OVA-loaded polymersomes could also induce OVA-specific CTL responsein vivo.CTLs, a type of T lymphocytes, can be activated by mature DCs [54] and kill infected cells or cancer cells by releasing perforin and granzymes [55].Antigen-loaded DC-based vaccines have been considered to directly induce a specific CTL response [56].Considering the increased MHC I presentation and IFN-γproduction by IMO-PS, we speculated that IMO-PS would effectively stimulate vaccine-induced CTL responses.To evaluate the OVA-specific CTL response induced by PS, mice were immunized with various PCEP-PS treated DCs.7 days after administration, splenocytes were obtained and re-stimulated with OVA peptide (SIINFEKL) in 1640 medium containing IL-2 for 72 h.Calcein-AM release assay was then used to evaluate cell viability and assess the CTL activity.The results showed that splenocytes harvested from mice immunized using IMO-PS treated DCs effectively induced CD8+T-mediated tumor cell lysis (Fig.S4A in Supporting information).The enhanced CTL responses could be contributed to the increasement of MHC I presentation and IFN-γproduction by IMO-PS.On the contrary, immunization with free OVA and OPS treated DCs failed to stimulate effective tumor specific CTL responses, in accordance with their poor effect on MHC I presentation and IFN-γsecretionin vitro.Compared with free OVA and OPS, the greatest cytotoxicity against EG7-OVA was achieved at the E:T ratio of 40:1 (Fig.S4B in Supporting information).The above results implied that IMO-PS treated DCs induced efficient antigenspecific CTL activity, demonstrating the synergistic effect of TLR4 and TLR7 signaling pathway on cellular immunity.

    Fig.3.Intracellular IFN-γ production was analyzed by FACS after splenocytes were restimulated with OVA peptide (1 μmol/L) for 96 h (n=3).Representative FACS plots of (A) IFN-γ producing CD4+ T cells and (B) IFN-γ producing CD8+ T cells.Mean frequencies of (C) IFN-γ producing CD4+ T cells and (D) IFN-γ producing CD8+ T cells.?P < 0.05, ??P < 0.01 and ???P < 0.001.

    To investigate the protective efficacy of PCEP-PS treated DCs against progressive EG7-OVA tumor, we immunized C57BL/6 mice with free OVA, O-PS, IO-PS, MO-PS, IMO-PS treated DCs (Fig.4A).PBS treated DCs were set as control group.One week after immunization, 1×106EG7-OVA cells were inoculated subcutaneously on the right back and the percentage of tumor-free mice was evaluated (Fig.4B).All mice in PBS+DCs group developed tumors within 4 days, while the mice injected with free OVA or O-PS treated DCs delayed to develop tumors within 12 days after tumor cell injection.On the contrary, 25% of mice administrated with IO-PS+DCs and MO-PS+DCs remained tumor free on day 54 post-challenge.Strikingly, the tumor free percentage was further increased to 37.5% for the mice vaccinated with IMOPS+DCs (Fig.4B).The survival rate was calculated up to 54 days after tumor inoculation.The mice vaccinated with IMO-PS showed 37.5% survival rate, while the IO-PS and MO-PS treated mice had 25% survival rate (Fig.4C).The results above suggest that IMOPS can elicit potent therapeutic anti-cancer immunity.Remarkably,the tumor-free mice in the IO-PS+DCs, MO-PS+DCs and IMOPS+DCs treated groups were re-challenged with 1×106EG7-OVA tumor cells on day 95 and they remained 100% tumor-free on day 155 (Fig.4D), confirming their capability of exhibiting long-term immunity against tumor reoccurrence.Combination of TLR4 and TLR7 ligands enhanced immune responses by synergistic effectviatriggering different pathways and thus influenced antigen dependent T-cell immune memory.These data above demonstrated that the combinational delivery of OVA, imiquimod and MPLA synergistically triggered anti-tumor immune responsesin vivo, thus achieving superior preventive effect against tumor challenge.

    Fig.4. In vivo protective efficacy of PS treated DCs.(A) Immunization schedule.(B)Percentage of tumor free mice after EG7-OVA tumor cells challenge.(C) Survival rate of EG7-OVA tumor-bearing mice.(D) Re-challenge study on tumor free mice in the IO-PS+DCs, MO-PS+DCs and IMO-PS+DCs group.Na?ve mice (n=6) were used as the control group.

    In summary, we have constructed cationic hybrid polymersomes (IMO-PS) for programmed co-delivery of OVA antigen and dual-adjuvants (IMQ and MPLA) for DC-based immunotherapy against cancer.The IMO-PS dramatically enhanced the OVA uptake in DCs and promoted DCs maturation and cytokines production.In addition, IMO-PS+DCs greatly improved DCs homing ability and OVA-specific CTL responses.Moreover, IMO-PS+DCs significantly extended tumor-free time, effectively suppressed tumor growth and greatly extended median survival time on the prophylactic EG7-OVA tumor model.Impressively, the tumor-free mice were re-challenged with EG7-OVA tumor cells on day 95 and they remained 100% tumor-free at the end of the observation time (155 days).The formulated co-delivery nanoplatform with dual agonists effectively stimulates DCs and holds great promise to be developed as DC-based vaccine for future immunotherapy treatment against cancer.

    Ethical compliance

    All animals were treated according to the regulations and guidelines of the Institute of Biomedical Engineering, Chinese Academy of Medical Science & Peking Union Medical College.

    Declaration of competing interest

    The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

    Acknowledgments

    This work was financially supported by National Natural Science Foundation of China (Nos.82072059 and 82172090),CAMS Initiative for Innovative Medicine (No.2021-I2M-1-058), the Fundamental Research Funds for the Central Universities (Nos.2019PT320028 and 2019-0831-03), Tianjin Municipal Natural Science Foundation (No.20JCYBJC00030).

    Supplementary materials

    Supplementary material associated with this article can be found, in the online version, at doi:10.1016/j.cclet.2022.02.022.

    69av精品久久久久久| 亚洲成人久久爱视频| 国产精品日韩av在线免费观看| АⅤ资源中文在线天堂| 深夜精品福利| 日韩三级伦理在线观看| 变态另类丝袜制服| 91久久精品国产一区二区三区| 日本爱情动作片www.在线观看| 嫩草影院入口| 午夜免费激情av| 久久久久网色| 又爽又黄无遮挡网站| 成年av动漫网址| 亚洲在久久综合| 精品熟女少妇av免费看| 色吧在线观看| 春色校园在线视频观看| 九九爱精品视频在线观看| 久久久久久久久久成人| 国产三级在线视频| 九九热线精品视视频播放| 能在线免费看毛片的网站| 精品日产1卡2卡| 欧美高清成人免费视频www| 国产熟女欧美一区二区| 久久中文看片网| 99国产精品一区二区蜜桃av| 久久久久免费精品人妻一区二区| 国产午夜福利久久久久久| 搡女人真爽免费视频火全软件| 嫩草影院新地址| 欧美3d第一页| 亚洲国产精品合色在线| 国产蜜桃级精品一区二区三区| 两个人视频免费观看高清| 日本黄色片子视频| 黄色一级大片看看| 久久精品国产自在天天线| 欧美性猛交╳xxx乱大交人| 麻豆成人午夜福利视频| 天堂av国产一区二区熟女人妻| 色哟哟哟哟哟哟| 国产男人的电影天堂91| 99久国产av精品国产电影| 精品人妻一区二区三区麻豆| 欧美三级亚洲精品| 国产精品一区二区三区四区久久| 久久九九热精品免费| 99久久成人亚洲精品观看| av福利片在线观看| 国产精品免费一区二区三区在线| 国产淫片久久久久久久久| 99热这里只有是精品50| 边亲边吃奶的免费视频| 嫩草影院精品99| 少妇熟女欧美另类| 内射极品少妇av片p| 久久99蜜桃精品久久| 青春草亚洲视频在线观看| 在线免费观看不下载黄p国产| 欧美潮喷喷水| 亚洲真实伦在线观看| 听说在线观看完整版免费高清| 久久精品夜色国产| 99久久精品一区二区三区| 天天躁夜夜躁狠狠久久av| 一级毛片电影观看 | 精品久久国产蜜桃| 精品无人区乱码1区二区| 精品国内亚洲2022精品成人| 久久久午夜欧美精品| 日日撸夜夜添| 搞女人的毛片| 简卡轻食公司| 国产v大片淫在线免费观看| 最近最新中文字幕大全电影3| 日韩在线高清观看一区二区三区| 成人高潮视频无遮挡免费网站| 波多野结衣高清无吗| 在线a可以看的网站| 免费av观看视频| 国产又黄又爽又无遮挡在线| 久久久久性生活片| 国产成人影院久久av| 偷拍熟女少妇极品色| 国产一区亚洲一区在线观看| 人人妻人人澡欧美一区二区| 成人亚洲欧美一区二区av| 在线国产一区二区在线| 国产91av在线免费观看| 一本精品99久久精品77| 欧美日本视频| 欧美区成人在线视频| 天天躁夜夜躁狠狠久久av| 国内揄拍国产精品人妻在线| 99热网站在线观看| 亚洲18禁久久av| av在线天堂中文字幕| 日韩欧美精品免费久久| 在线免费观看不下载黄p国产| 亚洲第一电影网av| 久久久欧美国产精品| 欧美日韩综合久久久久久| 亚洲成人久久性| 在线观看一区二区三区| 国产一区二区激情短视频| 免费人成视频x8x8入口观看| 最近2019中文字幕mv第一页| 日本三级黄在线观看| 日韩在线高清观看一区二区三区| 男人舔奶头视频| 乱人视频在线观看| 99久久人妻综合| 黄色日韩在线| 天堂√8在线中文| 国产真实乱freesex| 国产色爽女视频免费观看| 国产白丝娇喘喷水9色精品| 久久婷婷人人爽人人干人人爱| 亚洲精品久久国产高清桃花| 啦啦啦韩国在线观看视频| 亚洲精品自拍成人| 亚州av有码| 日本爱情动作片www.在线观看| 亚洲人与动物交配视频| 人妻久久中文字幕网| 可以在线观看毛片的网站| 日本成人三级电影网站| 久久99蜜桃精品久久| 又粗又硬又长又爽又黄的视频 | 观看免费一级毛片| 欧美xxxx性猛交bbbb| 丝袜喷水一区| 中文资源天堂在线| 成人毛片a级毛片在线播放| 欧美一区二区精品小视频在线| av天堂在线播放| 18禁黄网站禁片免费观看直播| 日韩中字成人| 综合色丁香网| 久久久国产成人免费| 久久精品国产鲁丝片午夜精品| 美女xxoo啪啪120秒动态图| 日韩制服骚丝袜av| 少妇人妻一区二区三区视频| a级毛片免费高清观看在线播放| 禁无遮挡网站| 别揉我奶头 嗯啊视频| 亚洲欧美日韩东京热| 国内精品美女久久久久久| 在线天堂最新版资源| 在线观看av片永久免费下载| 最新中文字幕久久久久| 国产国拍精品亚洲av在线观看| 亚洲精品粉嫩美女一区| 春色校园在线视频观看| 欧美成人精品欧美一级黄| 亚洲无线观看免费| 国产三级中文精品| 少妇的逼好多水| 午夜福利在线观看吧| 蜜桃亚洲精品一区二区三区| 小蜜桃在线观看免费完整版高清| 亚洲国产高清在线一区二区三| 国产伦精品一区二区三区视频9| 最近中文字幕高清免费大全6| 美女高潮的动态| 亚洲无线观看免费| 最好的美女福利视频网| 美女内射精品一级片tv| 97超碰精品成人国产| www日本黄色视频网| 一本久久精品| 熟妇人妻久久中文字幕3abv| 国产高清视频在线观看网站| 校园春色视频在线观看| 国产乱人视频| 丝袜美腿在线中文| 国产日韩欧美在线精品| 亚洲精品日韩av片在线观看| 免费观看的影片在线观看| 在线播放无遮挡| 国产高清激情床上av| 亚洲国产色片| av天堂中文字幕网| 我要搜黄色片| 99精品在免费线老司机午夜| 国产高清激情床上av| 熟女人妻精品中文字幕| h日本视频在线播放| 哪里可以看免费的av片| 久久草成人影院| 美女脱内裤让男人舔精品视频 | 亚洲人与动物交配视频| 最近2019中文字幕mv第一页| 色综合色国产| 成人特级av手机在线观看| 女的被弄到高潮叫床怎么办| 亚洲成人久久性| 综合色丁香网| 国产激情偷乱视频一区二区| 久久精品国产自在天天线| 久久久色成人| 三级经典国产精品| 亚洲av一区综合| 中文字幕免费在线视频6| 亚洲欧美精品自产自拍| 欧美激情在线99| 国内精品久久久久精免费| 日韩欧美精品v在线| 日韩欧美精品免费久久| 九草在线视频观看| a级毛片a级免费在线| 国产乱人偷精品视频| 日韩人妻高清精品专区| 18禁裸乳无遮挡免费网站照片| 91精品一卡2卡3卡4卡| 免费av毛片视频| 99热6这里只有精品| 三级男女做爰猛烈吃奶摸视频| 狂野欧美激情性xxxx在线观看| 国产精品爽爽va在线观看网站| 九九爱精品视频在线观看| 久久精品人妻少妇| 亚洲欧美清纯卡通| 国产毛片a区久久久久| 又粗又硬又长又爽又黄的视频 | 日韩欧美 国产精品| 在线观看美女被高潮喷水网站| 一本精品99久久精品77| 久久精品夜夜夜夜夜久久蜜豆| 亚洲国产精品成人久久小说 | 99在线视频只有这里精品首页| 久久精品国产亚洲av涩爱 | 91精品一卡2卡3卡4卡| 国产精品,欧美在线| 久久99热6这里只有精品| 美女脱内裤让男人舔精品视频 | 精品久久久久久久人妻蜜臀av| 男女下面进入的视频免费午夜| 欧美xxxx性猛交bbbb| 欧美日韩综合久久久久久| 国产精品女同一区二区软件| av专区在线播放| 26uuu在线亚洲综合色| 熟女人妻精品中文字幕| 成年女人看的毛片在线观看| 嫩草影院新地址| 国产伦精品一区二区三区四那| 久久99热这里只有精品18| 国产中年淑女户外野战色| 国产精品久久久久久久电影| 91在线精品国自产拍蜜月| 日韩一区二区视频免费看| 丰满的人妻完整版| 亚洲av不卡在线观看| 欧美+亚洲+日韩+国产| 午夜免费激情av| 看免费成人av毛片| 综合色丁香网| 尾随美女入室| 亚洲国产欧美人成| 联通29元200g的流量卡| 国产精品国产三级国产av玫瑰| 久久精品国产99精品国产亚洲性色| 99久久久亚洲精品蜜臀av| 性插视频无遮挡在线免费观看| 国产伦理片在线播放av一区 | 在线播放国产精品三级| 自拍偷自拍亚洲精品老妇| 日本欧美国产在线视频| 高清午夜精品一区二区三区 | 三级国产精品欧美在线观看| 一边摸一边抽搐一进一小说| 国产黄片美女视频| 女人十人毛片免费观看3o分钟| 亚洲av中文字字幕乱码综合| 亚洲内射少妇av| 日韩欧美国产在线观看| www日本黄色视频网| 久久人人爽人人片av| 成年女人看的毛片在线观看| videossex国产| 日本熟妇午夜| 青青草视频在线视频观看| 啦啦啦观看免费观看视频高清| 18禁黄网站禁片免费观看直播| 午夜爱爱视频在线播放| 亚洲成人av在线免费| 91在线精品国自产拍蜜月| 国产av麻豆久久久久久久| 我的女老师完整版在线观看| 亚洲第一电影网av| 菩萨蛮人人尽说江南好唐韦庄 | 成人鲁丝片一二三区免费| 久久久久久九九精品二区国产| 中国美女看黄片| 国内精品一区二区在线观看| 91在线精品国自产拍蜜月| 中文字幕久久专区| 精品午夜福利在线看| 亚洲人成网站在线播| 2021天堂中文幕一二区在线观| 亚洲国产精品成人久久小说 | 免费在线观看成人毛片| 国产乱人视频| 狂野欧美白嫩少妇大欣赏| 天堂中文最新版在线下载 | 欧美日韩国产亚洲二区| 亚洲最大成人av| 亚洲在线观看片| 久久婷婷人人爽人人干人人爱| 国产一级毛片在线| 国产三级在线视频| 干丝袜人妻中文字幕| 国产三级中文精品| 一级黄片播放器| 亚洲中文字幕一区二区三区有码在线看| 嫩草影院入口| 免费av不卡在线播放| 亚洲欧美日韩卡通动漫| 国产精品乱码一区二三区的特点| 免费大片18禁| 亚洲在久久综合| 九九热线精品视视频播放| 欧美潮喷喷水| 久久久精品94久久精品| 少妇的逼水好多| 国产成人精品婷婷| 国产色婷婷99| 99在线人妻在线中文字幕| 最近最新中文字幕大全电影3| 久久精品国产亚洲av香蕉五月| 欧美极品一区二区三区四区| 久久精品国产自在天天线| 男人狂女人下面高潮的视频| av国产免费在线观看| 美女高潮的动态| 国产亚洲5aaaaa淫片| 国产精品一区www在线观看| 天堂中文最新版在线下载 | 国产精品一区二区三区四区免费观看| 女人十人毛片免费观看3o分钟| 亚洲在久久综合| 欧美一区二区亚洲| 中国美白少妇内射xxxbb| or卡值多少钱| 国产午夜精品论理片| 中国国产av一级| 国产精品电影一区二区三区| 床上黄色一级片| 亚洲三级黄色毛片| 国国产精品蜜臀av免费| 久久久欧美国产精品| a级毛片免费高清观看在线播放| av专区在线播放| 一边亲一边摸免费视频| 天堂网av新在线| 97超视频在线观看视频| 免费观看精品视频网站| 亚洲自偷自拍三级| 亚洲av成人精品一区久久| 久久婷婷人人爽人人干人人爱| 91精品国产九色| 久久欧美精品欧美久久欧美| 午夜激情福利司机影院| 大型黄色视频在线免费观看| 成人性生交大片免费视频hd| 亚洲欧美精品自产自拍| 亚洲四区av| 欧美区成人在线视频| 毛片一级片免费看久久久久| av天堂中文字幕网| 午夜免费激情av| 人人妻人人澡人人爽人人夜夜 | 91狼人影院| 麻豆国产97在线/欧美| 国产 一区 欧美 日韩| 亚洲美女视频黄频| 日本三级黄在线观看| www日本黄色视频网| 欧美3d第一页| 深夜a级毛片| 韩国av在线不卡| 日韩一本色道免费dvd| 亚洲欧美日韩高清专用| 日本黄大片高清| 男插女下体视频免费在线播放| 老熟妇乱子伦视频在线观看| 一个人观看的视频www高清免费观看| 国产成人一区二区在线| 青青草视频在线视频观看| 日韩在线高清观看一区二区三区| 国产一区二区三区在线臀色熟女| 少妇的逼水好多| 亚洲欧洲日产国产| 欧美变态另类bdsm刘玥| 综合色av麻豆| 波多野结衣巨乳人妻| 成年女人永久免费观看视频| a级一级毛片免费在线观看| 国产国拍精品亚洲av在线观看| 日本一本二区三区精品| 深夜精品福利| 青春草视频在线免费观看| 亚洲av成人av| 可以在线观看毛片的网站| АⅤ资源中文在线天堂| 国产伦精品一区二区三区四那| 亚洲内射少妇av| 国产激情偷乱视频一区二区| 最近视频中文字幕2019在线8| 中文字幕av在线有码专区| 国产一区二区在线av高清观看| 联通29元200g的流量卡| 成年女人永久免费观看视频| 亚洲人成网站在线观看播放| 丰满乱子伦码专区| 97超碰精品成人国产| 国产精品精品国产色婷婷| 赤兔流量卡办理| 欧美性猛交黑人性爽| 99久久精品一区二区三区| 亚洲精品国产成人久久av| 国产午夜精品一二区理论片| 综合色av麻豆| 亚洲性久久影院| 国产精品女同一区二区软件| 国产精品国产高清国产av| 欧美激情在线99| 国产精品1区2区在线观看.| 日韩av在线大香蕉| 变态另类成人亚洲欧美熟女| 日韩高清综合在线| 成年女人看的毛片在线观看| 可以在线观看的亚洲视频| 边亲边吃奶的免费视频| 久久久久性生活片| 少妇人妻一区二区三区视频| 午夜精品国产一区二区电影 | 色哟哟·www| 日韩欧美在线乱码| 搡老妇女老女人老熟妇| av福利片在线观看| 国产亚洲av嫩草精品影院| 亚洲中文字幕一区二区三区有码在线看| 久久午夜亚洲精品久久| 1000部很黄的大片| 国产中年淑女户外野战色| 免费看a级黄色片| 成人鲁丝片一二三区免费| 亚洲成人中文字幕在线播放| 欧洲精品卡2卡3卡4卡5卡区| 日韩制服骚丝袜av| 国产高清三级在线| 国产一区二区激情短视频| 少妇人妻精品综合一区二区 | 欧美zozozo另类| 国产高清不卡午夜福利| 午夜精品在线福利| 天堂中文最新版在线下载 | 中文字幕免费在线视频6| 国产精品av视频在线免费观看| 99热这里只有是精品50| 中国国产av一级| 成年版毛片免费区| 99在线视频只有这里精品首页| 国产精品综合久久久久久久免费| 又爽又黄无遮挡网站| 久久久成人免费电影| 欧美最黄视频在线播放免费| 成人漫画全彩无遮挡| 日本熟妇午夜| 毛片女人毛片| 亚洲精品日韩在线中文字幕 | av又黄又爽大尺度在线免费看 | 大香蕉久久网| 国产精品嫩草影院av在线观看| 国产极品天堂在线| 啦啦啦啦在线视频资源| 亚洲自拍偷在线| 日本黄色片子视频| 蜜臀久久99精品久久宅男| 午夜爱爱视频在线播放| 国产一级毛片七仙女欲春2| 97热精品久久久久久| 成人高潮视频无遮挡免费网站| 亚洲无线在线观看| 成人欧美大片| 亚洲一级一片aⅴ在线观看| 日本在线视频免费播放| 亚洲国产精品sss在线观看| 99在线视频只有这里精品首页| 欧美最新免费一区二区三区| 69人妻影院| 成人永久免费在线观看视频| 成年女人永久免费观看视频| 亚洲第一电影网av| 亚洲欧美成人综合另类久久久 | 禁无遮挡网站| 国产精品久久久久久亚洲av鲁大| 亚洲美女搞黄在线观看| 精品久久国产蜜桃| 99久久九九国产精品国产免费| 亚洲最大成人手机在线| 人人妻人人澡欧美一区二区| 午夜久久久久精精品| 91久久精品国产一区二区三区| 老熟妇乱子伦视频在线观看| 午夜爱爱视频在线播放| 在线观看一区二区三区| 欧美潮喷喷水| 91久久精品国产一区二区成人| 国产免费一级a男人的天堂| 日本黄色片子视频| 99热只有精品国产| 国产伦在线观看视频一区| 精品久久久久久久末码| 日韩精品青青久久久久久| 成年av动漫网址| 国产黄a三级三级三级人| 亚洲国产精品合色在线| 简卡轻食公司| 一区福利在线观看| 成人一区二区视频在线观看| 亚洲aⅴ乱码一区二区在线播放| 我的老师免费观看完整版| 久久草成人影院| 亚洲国产欧美在线一区| 久久精品国产亚洲av涩爱 | 亚洲自拍偷在线| 久久久a久久爽久久v久久| 18禁在线播放成人免费| 人体艺术视频欧美日本| 99热全是精品| 国产精品一及| 中文资源天堂在线| 国产亚洲精品久久久com| 亚洲欧美日韩无卡精品| 精品久久久久久久久久免费视频| 日韩成人av中文字幕在线观看| 精品熟女少妇av免费看| 国产精品久久久久久久久免| av又黄又爽大尺度在线免费看 | 亚洲电影在线观看av| 国产视频内射| 国产精品人妻久久久影院| 欧美高清成人免费视频www| 午夜老司机福利剧场| 日产精品乱码卡一卡2卡三| 级片在线观看| 黄色视频,在线免费观看| 成人特级黄色片久久久久久久| 国产日本99.免费观看| 99热网站在线观看| 国产伦一二天堂av在线观看| 国产精品嫩草影院av在线观看| 五月伊人婷婷丁香| 免费一级毛片在线播放高清视频| 天天躁日日操中文字幕| 欧美+亚洲+日韩+国产| 日韩欧美国产在线观看| 少妇裸体淫交视频免费看高清| 欧美日韩一区二区视频在线观看视频在线 | 国产精品综合久久久久久久免费| 在线观看美女被高潮喷水网站| 91狼人影院| av在线播放精品| 日本成人三级电影网站| 最后的刺客免费高清国语| 一区二区三区高清视频在线| 久久精品夜色国产| 亚洲成人中文字幕在线播放| 天堂影院成人在线观看| 久久精品综合一区二区三区| 麻豆成人av视频| 国模一区二区三区四区视频| 男的添女的下面高潮视频| a级毛色黄片| 亚洲欧洲国产日韩| 观看免费一级毛片| 久久久精品94久久精品| 亚洲欧美日韩东京热| 最近手机中文字幕大全| 久久欧美精品欧美久久欧美| 成人鲁丝片一二三区免费| 婷婷色综合大香蕉| 国产 一区 欧美 日韩| 国产av不卡久久| 色5月婷婷丁香| 欧美xxxx黑人xx丫x性爽| 国产高潮美女av| 又爽又黄无遮挡网站| 亚洲av男天堂| 一级毛片aaaaaa免费看小| 欧美性感艳星| 久久精品国产亚洲av涩爱 | 美女被艹到高潮喷水动态| 长腿黑丝高跟| 午夜精品一区二区三区免费看| 亚洲无线在线观看| 麻豆一二三区av精品| 18禁在线播放成人免费| 国产精品99久久久久久久久| 国产成人a∨麻豆精品| 国产精品久久久久久久电影| 干丝袜人妻中文字幕| 国产精品三级大全| 国产熟女欧美一区二区| 99久国产av精品| 亚洲最大成人av| 人妻夜夜爽99麻豆av| 亚洲国产精品国产精品| 69人妻影院|